FDA granted Orphan Drug Designation to Debio 1143 for the treatment of ovarian cancer. Debio 1143 is an oral, small molecule inhibitor with a dual pro-apoptotic and immunomodulatory mode of action developed as a chemo/radio-sensitizer, according to Debiopharm International SA, the drug’s sponsor. Debiopharm plans to expand the clinical development of this therapy to patients...
Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.
